Shots:

• The discontinuation is based on Janssen's review of all available cusatuzumab data and in consideration of the evolving SOC for AML. Argenx regain its WW rights to cusatuzumab from Cilag
• The P-Ib ELEVATE interim data will support the development of the anti-CD70 Ab in AML- whereas argenx plans to evaluate options to enable a path forward
• Janssen will work with argenx to transition the cusatuzumab program back to argenx. Following the termination- argenx can elect that Janssen operationally support the treatment and follow-up of patients enrolled in ongoing cusatuzumab clinical studies

Ref: Janssen | Image: Janssen